Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The immunology of low-grade gliomas.

Neurosurgical focus - 1 Feb 2022

Haddad Alexander F, Young Jacob S, Oh Jun Yeop, Okada Hideho, Aghi Manish K

Abstract excerpt

Low-grade gliomas (LGGs), which harbor an isocitrate dehydrogenase (IDH) mutation, have a better prognosis than their high-grade counterparts; nonetheless, they remain incurable and impart significant negative impacts on patients' quality of life. Although immunotherapies represent a novel avenue of treatment for patients with LGGs, they have not yet been successful. Accurately selecting and evaluating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasm Grading

Share to Prognosis

Share to Quality of Life

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35104791
DOI: 10.3171/2021.11.FOCUS21587
PMCID: PMC9283531

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The immunology of low-grade gliomas.PMID 35104791Read ↗

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade GliomaSemantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.Semantic proximity Read ↗

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomasSemantic proximity Read ↗

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.Semantic proximity Read ↗

Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.Semantic proximity Read ↗

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade GliomasSemantic proximity Read ↗

Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine developmentSemantic proximity Read ↗

Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale AnalysisSemantic proximity Read ↗

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma.Semantic proximity Read ↗

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade GliomaSemantic proximity Read ↗

Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of GliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.